Immatics Surges 6% on the Deal With Moderna
<p>Shares of <a href='https://financialmodelingprep.com/financial-summary/IMTX'>Immatics (NASDAQ:IMTX)</a> surged more than 6% in pre-market today following the announcement of a cancer drug collaboration with vaccine giant <a href='https://financialmodelingprep.com/financial-summary/MRNA'>Moderna (NASDAQ:MRNA)</a>, valued at up to $1.8 billion.</p>
<p>The two companies have revealed a strategic research and development partnership aimed at pioneering innovative and game-changing therapies for cancer patients facing significant unmet medical needs.</p>
<p>Under the terms of the agreement, Immatics will receive an initial payment of $120 million, coupled with continuous research funding. Additionally, they have the potential to earn milestone payments linked to development, regulatory approvals, and commercial accomplishments, which could exceed $1.7 billion.</p>

NASDAQ:IMTX, NASDAQ:MRNA